For instance, it was found that CCNB2 is overexpressed in a variety of tumors, including gastric cancer, bladder cancer, prostate cancer, uterine corpus endometrial carcinoma (Shi et al., 2016; Huang et al., 2017; Han et al., 2018; Shen et al., 2018). Here, CCNB2 is linked to prostate cancer.